Leadership

Leadership

Senior
Leadership
Team

Frédéric Cren

Chairman, CEO and Co-Founder

Frédéric Cren has served as our Chief Executive Officer since co-founding Inventiva in 2011, and as the chairman of our board of directors since May 2016.

Previously, he served as the General Manager, Research of Abbott Laboratories from 2010 until 2012. Prior to Abbott, Mr. Cren held a number of roles at Solvay Pharmaceuticals, including Head of Business Strategy and Portfolio and Senior Vice-President of the Research Division, and at Laboratoires Fournier SA prior to its acquisition by Solvay in 2005. Positions at Laboratoires Fournier included: Vice-President, Strategic Marketing and Vice-President, U.S. Operations. Furthermore, Mr. Cren served as a member of the Executive Committees of both Solvay Pharmaceuticals and Laboratoires Fournier. Before joining the pharmaceutical industry, Mr. Cren was a consultant with The Boston Consulting Group in their healthcare practice for eight years.

Mr. Cren received a master’s degree in business administration from INSEAD, a master’s degree in international relations from Johns Hopkins University and a bachelor’s degree in economics from Paris IX Dauphine University.

Pierre Broqua, Ph.D.

CSO and Co-Founder

Pierre Broqua has served as our Chief Scientific Officer since co-founding Inventiva in 2011, and as our Deputy Chief Executive Officer and a member of our board of directors since May 2016.

Previously, Dr. Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010. Prior to Solvay, Dr. Broqua was the Director of Research Project for Laboratoires Fournier SA from 2002 to 2005.

He holds a Ph.D. in pharmacology from the University of Paris Descartes and a master’s degree in chemistry and biochemistry from Université Pierre et Marie Curie, Paris.

Jean Volatier

Chief Financial Officer

Jean Volatier has served as our Chief Financial Officer since August 2012.

Previously, Mr. Volatier was a senior consultant for I Care Environment, a consulting company, from January 2011 to October 2011, the interim Chief Financial Officer of the NAOS Group, a skin care company, from April 2010 to November 2010, the Chief Financial Officer of the Soufflet Group, an agro-industry company, from 2006 to 2008, the Financial Director—International Operations of Laboratoires Fournier SA, from 1999 to 2006 and the Head of Controlling for URGO Soins & Santé Laboratories, a pharmaceutical company, from 1996 to 1999.

Mr. Volatier began his career at PriceWaterhouseCoopers, where he worked from 1989 to 1996. He holds a master’s degree in management from Paris IX Dauphine University, PSL University, an executive specialized master’s degree in corporate social responsibility from MINES-ParisTech, PSL University, and the diplôme d’ études supérieures comptables et financières.

Marie-Paule Richard, M.D.

Chief Medical Officer

Marie-Paule Richard has served as our Chief Medical Officer since October 2018.

From 2014 to 2018, Dr. Richard was the Chief Medical Officer of TiGenix S.A., a Belgian biotechnology company that was acquired by Takeda Pharmaceutical Company Ltd. Dr. Richard also served as the Chief Medical Officer for AiCuris GmbH & Co., a pharmaceutical company, from 2010 to 2012, the Vice President of Clinical Development for Sanofi Pasteur, the vaccines division of the pharmaceutical company Sanofi S.A., from 2001 to 2007, the Global Senior Group Director for GlaxoSmithKline plc, a pharmaceutical company, from 2000 to 2001 and the Clinical Development Director for Aventis Pharma S.A. from 1993 to 2000.

Dr. Richard received a doctorate in medicine from the Medical School of Nancy University.

Kristina Meyer, Ph.D.

Head of Business Development

Kristina Meyer brings more than 15 years of commercial and business development experience in the biotech industry.

Kristina joined Inventiva in 2015 from Oxford BioTherapeutics where she was responsible for the outlicensing of pre-clinical oncology assets, inlicensing of antibody arming technologies, oncology target discovery collaborations and alliance management. Prior to Oxford BioTherapeutics she worked at Evotec in the USA and the UK where she had regional commercial responsibility for the discovery alliance business across various therapeutic areas and territories.

Dr. Meyer holds a Ph.D. in organic chemistry from the University of Frankfurt, Germany, and conducted post-doctoral research at Yale University in New Haven, CT, USA.